Received Mar 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 2 | Unknown | — |
The patient took second dose of Vivotif three days after first dose; Case reference number US-BN-2025-000901 is a spontaneous case report initially received from a nurse via Communication (reference number: USBAV25-1010) on 02-May-2025 and concerns an 18-years-old male patient. The patient's relevant medical history and concomitant medications were not provided. On 28-Apr-2025, the patient took first doses of Vivotif vaccine (batch number: unknown) at an unknown dose or route of administration for unknown indication. Oon 01-May-2025, three days after first dose, as reported the patient skipped two days and took the second dose of Vivotif vaccine (batch number: unknown) at an unknown dose or route of administration (explicitly coded as 'inappropriate schedule of vaccine administered'). At the time of the initial report, it was unknown if the patient experienced any adverse events due to Vivotif vaccine. No further information was provided.; Reporter's Comments: An 18-year-old male patient took the second dose of Vivotif vaccine 3 days after the first dose for unknown indication, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse events due to Vivotif vaccine. Inappropriate schedule of product administration is considered as listed per company convention. The patient's relevant medical history and concomitant medications were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: An 18-year-old male patient took the second dose of Vivotif vaccine 3 days after the first dose for unknown indication, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse events due to Vivotif vaccine. Inappropriate schedule of product administration is considered as listed per company convention. The patient's relevant medical history and concomitant medications were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: None